Wearable Device Tracks Movement in Several Muscle Diseases
Tests a wearable motion device to track movement in people with muscle diseases.
Plain-language title generated from the registry record
Registry title: Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study
Key facts
- Where
- Liège, BelgiumSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 80 years old?
Source: NCT05982119, who can take part
Where in Belgium
- CHR de la CitadelleLiège, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Liege
- Trial code
- NCT05982119
- Record updated
- 20 May 2025
- Original description
The objective of the ActiLiège Next study is to collect longitudinal data from patients and control subjects using a wearable magneto-inertial device. By collecting natural history data in various neuromuscular disorders (Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy, Myotonic Dystrophy 1, Charcot-Marie-Tooth, Centronuclear Myopathy, Congenital Muscular Dystrophy), we aim to validate digital outcome measures to continuously assess motor function in real-life.Read full original descriptionShow less
Gait Analysis Parameter, Stair Climbing and Upper Limb Evaluation in Patients With Muscular Pathology and in Control Subjects: The ActiLiège Next Study
The objective of the ActiLiège Next study is to collect longitudinal data from patients and control subjects using a wearable magneto-inertial device. By collecting natural history data in various neuromuscular disorders (Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy, Myotonic Dystrophy 1, Charcot-Marie-Tooth, Centronuclear Myopathy, Congenital Muscular Dystrophy), we aim to validate digital outcome measures to continuously assess motor function in real-life.
Inclusion: For the patients:; Genetically confirmed diagnosis of DMD, FSHD, DM1, CMT or FKRP mutations or confirmed CNM based on muscle biopsy; FSHD, DM1, CMT and CNM patients should be ambulant or in transition; DM1 and CMT patients should present sensori-motor signs on physical examination; Under the age of 20 years for patients with DMD, CNM or between the ages of 5 and 80 years for patients with FSHD, CMT and DM1; More than 2 years old for patients with FKRP mutations; Non-ambulant DMD patients must be able to remain seated in an arm- or a wheelchair for at least one hour; Patients with DMD treated with corticosteroids for at least 6 months or initiated corticosteroid at V0 (except for patients under 4); Signed informed consent form by patient himself or, in case of minor patients, signed informed consent form by patient's parents or legal guardians; For the control subjects:; Ambulant boys and girls under 20 years old; Signed informed consent form by patient him/herself or, in case of minor patients, signed informed consent form by patient's parents or legal guardians.
Exclusion: For the patients:; Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed; Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs (for ambulant patients); A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion; Patients who are participating in an interventional clinical trial; DMD patients in transition who are not on corticosteroids; For the control subjects:; Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs; Elite athletes (at the national level); A chronic or acute muscular, neurological, infectious, or inflammatory pathology within the 3-week period immediately prior to inclusion; An orthopedic, neuromuscular, or neurological pathology that affects the quality of the subject's walking gait.